webmaster-prism

About webmaster-prism

This author has not yet filled in any details.
So far webmaster-prism has created 86 blog entries.

What manufacturers need to know about Minnesota House Bill 400

2020-02-25T18:21:55+00:00July 30th, 2019|Categories: Blog|Tags: , |

We recently notified our clients and partners of several regulatory changes that will affect manufacturers and wholesalers doing business in Minnesota. In May 2019, Minnesota Governor Tim Walz signed House Bill 400, which created an Opioid Stewardship Advisory Council to confront the opioid addiction crisis and overdose epidemic. Parts of the law are already in effect as of July 1, 2019, and more pieces of the bill will [...]

New regulation requirements impacting your license

2020-02-25T18:22:58+00:00June 4th, 2019|Categories: Blog|Tags: , |

In the pharmaceutical industry, state licensing requirements can change at a moment’s notice. Though no central “hub” exists listing all licensing updates for each state, our team of experts works with state boards on a routine basis to track all license requirement updates. Recently, we’ve notified our clients and partners of changes that affect virtual manufacturers specifically in Arizona, Vermont, and New Hampshire. Government agencies in these states [...]

Doug Troy Joins Two Labs as New Chief Operating Officer

2020-02-25T18:26:25+00:00May 2nd, 2019|Categories: Blog|Tags: |

At Two Labs, we value partnership. We work hard to make sure our clients view us as an extended part of their team, and not just another vendor. As the pharma market continues to evolve, we are excited to expand our team so that we can provide even more value to our clients as they navigate the path of bringing their products to market. Two Labs welcomes Doug Troy [...]

Two Labs Joins Global Celebration of Rare Disease Day

2020-02-26T13:50:45+00:00February 28th, 2019|Categories: Blog|Tags: , , |

Since 2008, Rare Disease Day has been on the last day of February – which every four years is a rare 29th of the month. The observance was created to drive awareness of the 6,000 existing rare diseases that affect 1 in every 20 of us. As a way of demonstrating our support, we joined in on Rare Disease Day’s face-painting event at our offices, along with donations [...]

Current and Future Oncology Management in the United States

2020-03-02T20:05:08+00:00February 7th, 2019|Categories: News|Tags: |

Originally posted by the Journal of Managed Care & Specialty Pharmacy Volume 25 Issue (2) Anne Runyan, BA; Jordan Banks, MPA; and Daniele Severi Bruni, MS MKO Global Partners, Powell, Ohio. J Manag Care Spec Pharm, 2019 Feb;25(2):272-281. Abstract BACKGROUND: The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital [...]

Current and Future Oncology Management in the United States

2020-02-26T13:56:46+00:00February 1st, 2019|Categories: Blog|Tags: , |

The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital stays, surgery, home care, transportation and travel, and caregiving. This study focuses on the cost of medication from the viewpoint of U.S. payers. Although new tools for managing these costs have been gaining attention, prices continue to rise, and [...]

Innovative Access Agreements

2020-05-13T15:05:43+00:00January 1st, 2019|Categories: Blog|Tags: , , |

A potential payer solution for Cell & Gene Therapies A US and European perspective Payer concerns over increasing cost of therapies and uncertainty of clinical data have led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). For the purpose of this review we will refer to them collectively as IAA. The [...]

NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab

2020-03-02T20:05:42+00:00November 1st, 2018|Categories: News|Tags: |

With the recent patent expiry of Humira® (adalimumab) in Europe, NHS England last week published a press release reiterating their goal of realizing £300 million in annual savings through the adoption of best value biologic medicines (originator or biosimilar) by 2021. With more than 46,000 patients in the UK and an annual cost of greater than £400 million, Humira represents the largest spend on a single drug by the NHS and a significant opportunity [...]

Comments Off on NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab

Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market

2020-02-26T14:02:40+00:00November 1st, 2018|Categories: Blog|Tags: , |

Although biosimilars have taken off in Europe, they have yet to gain significant traction in the United States. More than thirty biosimilars have been approved and twenty-six are marketed in Europe. In the US, there are only eleven biosimilars approved with only five marketed: Zarxio, Fulphila, Retacrit, Renflexis, and Inflectra. Read the full report by downloading this paper. Download White Paper

Two Labs Acquires Pennside Partners Ltd.

2020-02-26T14:08:38+00:00October 23rd, 2018|Categories: Blog|Tags: , , |

We’re excited to share today that as of  October 18, 2018, Two Labs has acquired Pennside Partners Ltd., a leading international provider of market insights, benchmarking, and competitive intelligence services for the pharmaceutical, biotech, and medical device sectors. This acquisition enhances Two Labs’ suite of services with complementary competitive intelligence services and extends its capabilities into clinical product insights allowing us to better meet clients’ evolving needs. At our [...]

Go to Top